RECITALSResearch License and Option Agreement • January 15th, 1999 • Abgenix Inc • Biological products, (no disgnostic substances) • California
EXHIBIT 10.5 (REDACTED)Research, License and Option Agreement • August 12th, 1999 • Agritope Inc • Services-commercial physical & biological research • California
ContractResearch License and Option Agreement • January 12th, 2021
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
ContractResearch License and Option Agreement • January 15th, 2021
Selecta Biosciences and IGAN Biosciences Enter into Research License and Option Agreement to Study Selecta’s ImmTOR™ Immune Tolerance Platform in Combination with IGAN’s IgA Protease for the Treatment of IgA Nephropathy
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Research License and Option Agreement • September 9th, 2020 • Codiak BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Research License and Option Agreement (“Agreement”) is effective as of June 17, 2020 (“Effective Date”) made by and between CODIAK BIOSCIENCES, INC. a Delaware corporation having offices at 35 CambridgePark Drive, Suite 500, Cambridge, MA 02140 (“Codiak”), and SAREPTA THERAPEUTICS, INC., a Delaware corporation having offices at 215 First Street, Cambridge, MA 02142 (“Sarepta”). Each of Codiak and Sarepta may be referred to in this Agreement individually as a “Party” or together as the “Parties.”
RESEARCH LICENSE AND OPTION AGREEMENTResearch License and Option Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This Research License and Option Agreement (this “Agreement”) is made effective as of June 11, 2008 (the “Effective Date”), by and between Archemix Corp, a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“Archemix”), and Ribomic, Inc., a corporation organized under the laws of Japan with offices at Shirokanedai Usui Building, 3-16-13 Shirokanedai, Minato-ku, Tokyo 108-0071 Japan (“Ribomic”). Archemix and Ribomic are each sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties.”
RESEARCH, LICENSE AND OPTION AGREEMENT between BIOGENERIX AG and NEOSE TECHNOLOGIES, INC. April 27, 2005Research, License and Option Agreement • August 4th, 2005 • Neose Technologies Inc • Medicinal chemicals & botanical products
This RESEARCH, LICENSE AND OPTION AGREEMENT, dated as of April 27, 2005 (“Agreement”), is made by and between BIOGENERIX AG, a corporation organized under the laws of the Federal Republic of Germany (“BioGeneriX”), and NEOSE TECHNOLOGIES, INC., a Delaware corporation (“Neose”). BioGeneriX and Neose are sometimes referred to herein, individually, as a “party” and, collectively, as the “parties.”
RESEARCH LICENSE AND OPTION AGREEMENT Dated April 27, 2012 By and Between Ligand Pharmaceuticals Incorporated and Ares Trading SAResearch License and Option Agreement • August 8th, 2012 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS RESEARCH LICENSE AND OPTION AGREEMENT (the “Agreement”) is dated as of April 27, 2012 (the “Effective Date”) by and between Ligand Pharmaceuticals Incorporated, a corporation organized under the laws of the US state of Delaware having its place of business at 11085 North Torrey Pines Road, La Jolla, California 92037, USA (“Ligand”), and ARES Trading SA, a corporation organized under Swiss law having a place of business at Zone Industrielle de l’Ouriettaz, 1170 Aubonne SWITZERLAND (“Merck”). Ligand and Merck may be referred to herein as a “Party” or, collectively, as “Parties”.
RESEARCH, LICENSE AND OPTION AGREEMENTResearch, License and Option Agreement • August 15th, 2016 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
This research, license and option agreement (the “Agreement”) is entered into as of May 5th, 2016 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and WAVE Life Sciences Ltd., a Singapore corporation having a principal place of business at 733 Concord Avenue, Cambridge, MA 02138 (“Wave”). Pfizer and Wave may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment No. 1 to Research, License and Option Agreement (“Amendment No. 1”)Research, License and Option Agreement • March 12th, 2018 • Wave Life Sciences Ltd. • Pharmaceutical preparations
WHEREAS, the parties hereto desire to amend certain terms of the Agreement in order to provide for an extension of the period of time to nominate the Additional Programs,
